FR2792204B1 - Vaccin anti-vih-1 comprenant tout en partie de la proteine tat de vih-1 - Google Patents

Vaccin anti-vih-1 comprenant tout en partie de la proteine tat de vih-1

Info

Publication number
FR2792204B1
FR2792204B1 FR9904610A FR9904610A FR2792204B1 FR 2792204 B1 FR2792204 B1 FR 2792204B1 FR 9904610 A FR9904610 A FR 9904610A FR 9904610 A FR9904610 A FR 9904610A FR 2792204 B1 FR2792204 B1 FR 2792204B1
Authority
FR
France
Prior art keywords
hiv
vaccine
tat protein
tat
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR9904610A
Other languages
English (en)
Other versions
FR2792204A1 (fr
Inventor
Erwann Loret
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR9904610A priority Critical patent/FR2792204B1/fr
Priority to FR9916633A priority patent/FR2792206B1/fr
Priority to PL353033A priority patent/PL197666B1/pl
Priority to AT00918952T priority patent/ATE280586T1/de
Priority to AU39724/00A priority patent/AU775560B2/en
Priority to HU0200841A priority patent/HUP0200841A2/hu
Priority to IL14588400A priority patent/IL145884A0/xx
Priority to ES00918952T priority patent/ES2231178T3/es
Priority to PT00918952T priority patent/PT1169057E/pt
Priority to EP20000918952 priority patent/EP1169057B1/fr
Priority to JP2000610400A priority patent/JP4860823B2/ja
Priority to DE60015312T priority patent/DE60015312T2/de
Priority to DK00918952T priority patent/DK1169057T3/da
Priority to BR0009758-6A priority patent/BR0009758A/pt
Priority to MXPA01010482A priority patent/MXPA01010482A/es
Priority to PCT/FR2000/000938 priority patent/WO2000061067A2/fr
Priority to CA2370563A priority patent/CA2370563C/fr
Publication of FR2792204A1 publication Critical patent/FR2792204A1/fr
Application granted granted Critical
Publication of FR2792204B1 publication Critical patent/FR2792204B1/fr
Priority to NO20014841A priority patent/NO326603B1/no
Priority to IL145884A priority patent/IL145884A/en
Priority to KR10-2001-7013031A priority patent/KR100725637B1/ko
Priority to ZA200108398A priority patent/ZA200108398B/xx
Priority to HK02105105.9A priority patent/HK1044463B/zh
Priority to US10/969,191 priority patent/US7087377B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR9904610A 1999-04-13 1999-04-13 Vaccin anti-vih-1 comprenant tout en partie de la proteine tat de vih-1 Expired - Lifetime FR2792204B1 (fr)

Priority Applications (23)

Application Number Priority Date Filing Date Title
FR9904610A FR2792204B1 (fr) 1999-04-13 1999-04-13 Vaccin anti-vih-1 comprenant tout en partie de la proteine tat de vih-1
FR9916633A FR2792206B1 (fr) 1999-04-13 1999-12-29 Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1
PCT/FR2000/000938 WO2000061067A2 (fr) 1999-04-13 2000-04-12 Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1
AU39724/00A AU775560B2 (en) 1999-04-13 2000-04-12 Anti-HIV 1 vaccine comprising the entire or part of the TAT HIV-1 protein
HU0200841A HUP0200841A2 (en) 1999-04-13 2000-04-12 Anti-hiv 1 vaccine comprising the entire or part of the tat hiv-1 protein
IL14588400A IL145884A0 (en) 1999-04-13 2000-04-12 Anti-hiv 1 vaccine comprising the entire or part of the tat hiv-1 protein
ES00918952T ES2231178T3 (es) 1999-04-13 2000-04-12 Vacunaanti.
PT00918952T PT1169057E (pt) 1999-04-13 2000-04-12 Vacina anti-hiv-1 compreendendo o todo ou parte de uma proteina tat de vih-1
EP20000918952 EP1169057B1 (fr) 1999-04-13 2000-04-12 Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1
JP2000610400A JP4860823B2 (ja) 1999-04-13 2000-04-12 Ｈｉｖ−１のｔａｔタンパク質の全体又は一部を含有する抗ｈｉｖ−１ワクチン
DE60015312T DE60015312T2 (de) 1999-04-13 2000-04-12 Anti-hiv-1 impfstoff enthaltend das ganzen hiv-1 tat protein oder ein teil davon
DK00918952T DK1169057T3 (da) 1999-04-13 2000-04-12 Anti-HIV-1-vaccine, der omfatter det hele eller en del af HIV-1-Tat-proteinet
PL353033A PL197666B1 (pl) 1999-04-13 2000-04-12 Szczepionka anty-HIV-1, sposób wytwarzania poliklonalnych przeciwciał anty-TAT, sposób wykrywania obecności białka TAT w próbce biologicznej, zestaw do diagnozowania zakażenia HIV i sposób wytwarzania wariantu TAT
MXPA01010482A MXPA01010482A (es) 1999-04-13 2000-04-12 Vacuna anti-vih-1 que comprende toda o parte de la proteina tat de vih-1.
AT00918952T ATE280586T1 (de) 1999-04-13 2000-04-12 Anti-hiv-1 impfstoff enthaltend das ganzen hiv-1 tat protein oder ein teil davon
CA2370563A CA2370563C (fr) 1999-04-13 2000-04-12 Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1
BR0009758-6A BR0009758A (pt) 1999-04-13 2000-04-12 Vacina anti-hiv, processos de preparação de anticorpos policlonais, para evidenciação da presença da proteìna tat ou uma parte da proteìna tat em uma amostra biológica e de sìntese de uma variante tat e kit diagnóstico
NO20014841A NO326603B1 (no) 1999-04-13 2001-10-04 Anti-HIV-1 vaksine som omfatter et HIV-1 TAT Oyi protein eller ekspressjonsvektor omfattende nukleotidsekvens som koder for variantproteinet og fremgangsmate for fremstilling av anti-Tat polyklonale antistoffer og fremstilling av Tat-varianten
IL145884A IL145884A (en) 1999-04-13 2001-10-11 Anti-HIV-1 vaccine containing some or all of the TAT-HIV protein
KR10-2001-7013031A KR100725637B1 (en) 1999-04-13 2001-10-12 Anti-HIV-1 vaccine comprising all or part of the HIV-1 Tat protein
ZA200108398A ZA200108398B (en) 1999-04-13 2001-10-12 Anti-HIV-1 vaccine comprising all or part of the HIV-1 Tat protein.
HK02105105.9A HK1044463B (zh) 1999-04-13 2002-07-09 包含全部或部份反式激活轉綠基因人類免疫力缺乏病毒-1蛋白的抗人類免疫力缺乏病毒-1疫苗
US10/969,191 US7087377B2 (en) 1999-04-13 2004-10-21 Method and kit for detection of tat protein with anti-tat oyi antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9904610A FR2792204B1 (fr) 1999-04-13 1999-04-13 Vaccin anti-vih-1 comprenant tout en partie de la proteine tat de vih-1

Publications (2)

Publication Number Publication Date
FR2792204A1 FR2792204A1 (fr) 2000-10-20
FR2792204B1 true FR2792204B1 (fr) 2001-07-13

Family

ID=9544341

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9904610A Expired - Lifetime FR2792204B1 (fr) 1999-04-13 1999-04-13 Vaccin anti-vih-1 comprenant tout en partie de la proteine tat de vih-1

Country Status (2)

Country Link
FR (1) FR2792204B1 (fr)
ZA (1) ZA200108398B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2834717B1 (fr) * 2002-01-11 2004-12-10 Bio Merieux Mutants de la proteine tat du virus vih-1
KR100468316B1 (ko) 2002-01-29 2005-01-27 주식회사 웰진 Ｄｎａ의 세포 또는 조직 내 전달 효율을 높이는 펩타이드
WO2018085836A1 (fr) * 2016-11-07 2018-05-11 Colorado State University Research Foundation Peptides anti-vih

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2700169B1 (fr) * 1993-01-04 1995-03-24 Transgene Sa Nouveaux variants trans-dominants TAT du virus de l'immunodéficience humaine.

Also Published As

Publication number Publication date
ZA200108398B (en) 2002-09-25
FR2792204A1 (fr) 2000-10-20

Similar Documents

Publication Publication Date Title
DK1210113T3 (da) Kombinerede vaccinepræparater
ATE447947T1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
ATE413188T1 (de) Menschliche papillomavirus impfstoff- formulierungen
NO20020304L (no) Konserverte farmasoytiske preparater
BR0113822A (pt) Vacina
DE60020763D1 (de) Sterilisationssystem
NO20013736L (no) Pyrazolkarboksylsyrederivater, deres fremstilling og farmasöytiske preparater inneholdende de samme
DZ2462A1 (fr) Vaccin antigrippal.
CY1105008T1 (el) Αντιμικροβιακη ενεργοτητα του πρωτου κατιονικου συγκροτηματος της ανθρωπινης λακτοφερρινης
EE200200349A (et) Antiprogestiinsete omadustega ravimite manustamise vahendid
NO20071303L (no) Farmasoytiske preparater
DE50008973D1 (de) Bipolares medizinisches instrument
DK0956858T3 (da) Farmaceutiske præparater indeholdende lactobacilli til behandling af vaginale infektioner
DK1202965T3 (da) Indolderivater, fremgangsmåde til fremstilling deraf, farmaceutiske præparater indeholdende disse og deres medicinske anvendelse
PT1169460E (pt) Preparacao de moleculas biologicamente activas.
PT1173187E (pt) Preparacoes combinadas compreendendo derivados de antraciclina
NO20015670D0 (no) Forbedrede farmasöytiske formuleringer
DZ3219A1 (fr) Vaccin
EE05255B1 (et) Nahal kasutatavad parasititsiidide vettsisaldavad preparaadid
HUP0200841A2 (en) Anti-hiv 1 vaccine comprising the entire or part of the tat hiv-1 protein
ATE247981T1 (de) Proteinenthaltende pharmazeutische zubereitung
FR2792529B1 (fr) Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines
DE60032884D1 (de) Blutbehandlungssystem
NO20022022D0 (no) N-guanidinoalkylamider, deres fremstilling, deres anvendelse og farmasöytiske preparater omfattende disse
FR2792204B1 (fr) Vaccin anti-vih-1 comprenant tout en partie de la proteine tat de vih-1

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20